SPONSOR
National Institute of Cancerología
Total Trials
2
Recruiting
2
Phases
Phase 2
National Institute of Cancerología is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Cervical Cancer, Uterine Cervical Neoplasm.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — National Institute of Cancerología
How many clinical trials has National Institute of Cancerología sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by National Institute of Cancerología, of which 2 are actively recruiting participants. These trials cover conditions including Cervical Cancer, Uterine Cervical Neoplasm. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does National Institute of Cancerología research focus on?
National Institute of Cancerología clinical trials span Cervical Cancer, Uterine Cervical Neoplasm. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a National Institute of Cancerología clinical trial?
To participate in a National Institute of Cancerología trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all National Institute of Cancerología trials with current recruitment status updated daily.
Clinical Trials by National Institute of Cancerología
NCT03101995 Phase 2
Recruiting
Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease
Cervical Cancer
NCT06560697
Recruiting
Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma
Uterine Cervical Neoplasm
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology